Phase 3 Readout

Phase 3 Topline: An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and

Indication
Advanced Malignancies

Other upcoming events for ONC

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment W
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy and Safety of
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy a
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or C
Phase 3 ReadoutPhase 3 Topline: An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and — ONC Phase 3 Readout | BioSniper